A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
provide for reciprocal marketing approval of certain 
drugs, biological products, and devices that are author-
ized to be lawfully marketed abroad, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Reciprocity Ensures 
4
Streamlined Use of Lifesaving Treatments Act of 2021’’. 
5
23:57 Feb 21, 2021
H724
2 
•HR 724 IH
SEC. 2. RECIPROCAL MARKETING APPROVAL FOR CERTAIN 
1
DRUGS, BIOLOGICAL PRODUCTS, AND DE-
2
VICES. 
3
The Federal Food, Drug, and Cosmetic Act is amend-
4
ed by inserting after section 524A of such Act (21 U.S.C. 
5
360n–1) the following: 
6
‘‘SEC. 524B. RECIPROCAL MARKETING APPROVAL. 
7
‘‘(a) IN GENERAL.—A covered product with recip-
8
rocal marketing approval in effect under this section is 
9
deemed to be subject to an application or premarket notifi-
10
cation for which an approval or clearance is in effect under 
11
section 505(c), 510(k), or 515 of this Act or section 
12
351(a) of the Public Health Service Act, as applicable. 
13
‘‘(b) ELIGIBILITY.—The Secretary shall, with respect 
14
to a covered product, grant reciprocal marketing approval 
15
if— 
16
‘‘(1) the sponsor of the covered product submits 
17
a request for reciprocal marketing approval; and 
18
‘‘(2) the request demonstrates to the Sec-
19
retary’s satisfaction that— 
20
‘‘(A) the covered product is authorized to 
21
be lawfully marketed in one or more of the 
22
countries included in the list under section 
23
802(b)(1) or in the United Kingdom; 
24
23:57 Feb 21, 2021
H724
3 
•HR 724 IH
‘‘(B) absent reciprocal marketing approval, 
1
the covered product is not approved or cleared 
2
for marketing, as described in subsection (a); 
3
‘‘(C) the Secretary has not, because of any 
4
concern relating to the safety or effectiveness of 
5
the covered product, rescinded or withdrawn 
6
any such approval or clearance; 
7
‘‘(D) the authorization to market the cov-
8
ered product in one or more of the countries in-
9
cluded in the list under section 802(b)(1) or in 
10
the United Kingdom has not, because of any 
11
concern relating to the safety or effectiveness of 
12
the covered product, been rescinded or with-
13
drawn; 
14
‘‘(E) the covered product is not a banned 
15
device under section 516; and 
16
‘‘(F) there is a public health or unmet 
17
medical need for the covered product in the 
18
United States. 
19
‘‘(c) SAFETY AND EFFECTIVENESS.— 
20
‘‘(1) IN GENERAL.—The Secretary— 
21
‘‘(A) may decline to grant reciprocal mar-
22
keting approval under this section with respect 
23
to a covered product if the Secretary affirma-
24
tively determines that the covered product— 
25
23:57 Feb 21, 2021
H724
4 
•HR 724 IH
‘‘(i) is a drug that is not safe and ef-
1
fective; or 
2
‘‘(ii) is a device for which there is no 
3
reasonable assurance of safety and effec-
4
tiveness; and 
5
‘‘(B) may condition reciprocal marketing 
6
approval under this section on the conduct of 
7
specified postmarket studies, which may include 
8
such studies pursuant to a risk evaluation and 
9
mitigation strategy under section 505–1. 
10
‘‘(2) REPORT TO CONGRESS.—Upon declining 
11
to grant reciprocal marketing approval under this 
12
section with respect to a covered product, the Sec-
13
retary shall— 
14
‘‘(A) include the denial in a list of such de-
15
nials for each month; and 
16
‘‘(B) not later than the end of the respec-
17
tive month, submit the list to the Committee on 
18
Energy and Commerce of the House of Rep-
19
resentatives and the Committee on Health, 
20
Education, Labor, and Pensions of the Senate. 
21
‘‘(d) REQUEST.—A request for reciprocal marketing 
22
approval shall— 
23
‘‘(1) be in such form, be submitted in such 
24
manner, and contain such information as the Sec-
25
23:57 Feb 21, 2021
H724
5 
•HR 724 IH
retary deems necessary to determine whether the cri-
1
teria listed in subsection (b)(2) are met; and 
2
‘‘(2) include, with respect to each country in-
3
cluded in the list under section 802(b)(1) where the 
4
covered product is authorized to be lawfully mar-
5
keted, as described in subsection (b)(2)(A), an 
6
English translation of the dossier issued by such 
7
country to authorize such marketing. 
8
‘‘(e) TIMING.—The Secretary shall issue an order 
9
granting, or declining to grant, reciprocal marketing ap-
10
proval with respect to a covered product not later than 
11
30 days after the Secretary’s receipt of a request under 
12
subsection (b)(1) for the product. An order issued under 
13
this subsection shall take effect subject to Congressional 
14
disapproval under subsection (g). 
15
‘‘(f) LABELING; DEVICE CLASSIFICATION.—During 
16
the 30-day period described in subsection (e)— 
17
‘‘(1) the Secretary and the sponsor of the cov-
18
ered product shall expeditiously negotiate and final-
19
ize the form and content of the labeling for a cov-
20
ered product for which reciprocal marketing ap-
21
proval is to be granted; and 
22
‘‘(2) in the case of a device for which reciprocal 
23
marketing approval is to be granted, the Secretary 
24
shall— 
25
23:57 Feb 21, 2021
H724
6 
•HR 724 IH
‘‘(A) classify the device pursuant to section 
1
513; and 
2
‘‘(B) determine whether, absent reciprocal 
3
marketing approval, the device would need to be 
4
cleared pursuant to section 510(k) or approved 
5
pursuant to section 515 to be lawfully marketed 
6
under this Act. 
7
‘‘(g) CONGRESSIONAL DISAPPROVAL OF FDA OR-
8
DERS.— 
9
‘‘(1) IN GENERAL.—A decision of the Secretary 
10
to decline to grant reciprocal marketing approval 
11
under this section shall not take effect if a joint res-
12
olution of disapproval of the decision is enacted. 
13
‘‘(2) PROCEDURE.— 
14
‘‘(A) IN
GENERAL.—Subject to subpara-
15
graph (B), the procedures described in sub-
16
sections (b) through (g) of section 802 of title 
17
5, United States Code, shall apply to the con-
18
sideration of a joint resolution under this sub-
19
section. 
20
‘‘(B) TERMS.—For purposes of this sub-
21
section— 
22
‘‘(i) 
the 
reference 
to 
‘section 
23
801(a)(1)’ in section 802(b)(2)(A) of title 
24
23:57 Feb 21, 2021
H724
7 
•HR 724 IH
5, United States Code, shall be considered 
1
to refer to subsection (c)(2); and 
2
‘‘(ii) 
the 
reference 
to 
‘section 
3
801(a)(1)(A)’ in section 802(e)(2) of title 
4
5, United States Code, shall be considered 
5
to refer to subsection (c)(2). 
6
‘‘(3) 
EFFECT
OF
CONGRESSIONAL
DIS-
7
APPROVAL.—Reciprocal marketing approval under 
8
this section with respect to the applicable covered 
9
product shall take effect upon enactment of a joint 
10
resolution of disapproval under this subsection. 
11
‘‘(h) APPLICABILITY OF RELEVANT PROVISIONS.— 
12
The provisions of this Act shall apply with respect to a 
13
covered product for which reciprocal marketing approval 
14
is in effect to the same extent and in the same manner 
15
as such provisions apply with respect to a product for 
16
which approval or clearance of an application or pre-
17
market notification under section 505(c), 510(k), or 515 
18
of this Act or section 351(a) of the Public Health Service 
19
Act, as applicable, is in effect. 
20
‘‘(i) FEES FOR REQUEST.—For purposes of imposing 
21
fees under chapter VII, a request for reciprocal marketing 
22
approval under this section shall be treated as an applica-
23
tion or premarket notification for approval or clearance 
24
23:57 Feb 21, 2021
H724
8 
•HR 724 IH
under section 505(c), 510(k), or 515 of this Act or section 
1
351(a) of the Public Health Service Act, as applicable. 
2
‘‘(j) OUTREACH.—The Secretary shall conduct an 
3
outreach campaign to encourage the sponsors of covered 
4
products that are potentially eligible for reciprocal mar-
5
keting approval to request such approval. 
6
‘‘(k) COVERED PRODUCT DEFINED.—In this section, 
7
the term ‘covered product’ means a drug, biological prod-
8
uct, or device.’’. 
9
Æ 
23:57 Feb 21, 2021
H724
